Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma-Reference-Cited by-同舟云学术

Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma

Published:2024-09 Issue:9 Volume:30 Page:876-884
ISSN:2666-6367
Container-title:Transplantation and Cellular Therapy
language:en
Short-container-title:Transplantation and Cellular Therapy

Author:

Wesson William^ORCID,Dima Danai,Suleman Nahid,Saif Md Saiful Islam,Tabak Carine^ORCID,Logan Emerson,Davis James A.^ORCID,McGann Mary^ORCID,Furqan Fateeha,Mohan Meera,Rashid Aliya,Abdallah Al–Ola,Ullah Fauzia^ORCID,Shune Leyla^ORCID,Mushtaq Muhammad Umair,Raza Shahzad,McGuirk Joseph^ORCID,Hamadani Mehdi^ORCID,Anwer Faiz^ORCID,Hashmi Hamza,Ahmed Nausheen^ORCID

Publisher

Elsevier BV

Reference30 articles.

1. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study;Berdeja;Lancet,2021

2. Ciltacabtagene autoleucel, an anti–b-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up;Martin;J Clin Oncol,2022

3. Idecabtagene vicleucel in relapsed and refractory multiple myeloma;Munshi;N Engl J Med,2021

4. Ide-cel or standard regimens in relapsed and refractory multiple myeloma;Rodriguez-Otero;N Engl J Med,2023

5. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma;San-Miguel;New Engl J Med,2023

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myeloma CAR T-cell therapy toxicity timing: What is the right amount of post-treatment monitoring for our patients?;Transplantation and Cellular Therapy;2024-09

2. CAR-T cell therapy in relapsed or refractory multiple myeloma and access in Turkey;Frontiers in Medicine;2024-08-28

3. Comparing the Differences in Adverse Events among Chimeric Antigen Receptor T-Cell Therapies: A Real-World Pharmacovigilance Study;Pharmaceuticals;2024-08-05